Acceleron Pharma Inc EBITDA margin
Mi az Acceleron Pharma Inc EBITDA margin?
A EBITDA margin az Acceleron Pharma Inc - -222.82%
Mi a EBITDA margin meghatározása?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin a Health Care szektor a NASDAQ-on cégekben a Acceleron Pharma Inc -hoz képest
Mit csinál Acceleron Pharma Inc?
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
ebitda margin -hoz hasonló cégek Acceleron Pharma Inc
- Star Royalties nak EBITDA margin -224.44% van
- General Assembly nak EBITDA margin -223.97% van
- Blockmint Technologies nak EBITDA margin -223.45% van
- Hydrocarbon Dynamics nak EBITDA margin -223.22% van
- Vast Resources plc nak EBITDA margin -223.12% van
- uniQure N.V nak EBITDA margin -223.09% van
- Acceleron Pharma Inc nak EBITDA margin -222.82% van
- Greenway Mining nak EBITDA margin -222.31% van
- Qudian Inc nak EBITDA margin -221.61% van
- Lumos Diagnostics nak EBITDA margin -220.54% van
- Gossamer Bio nak EBITDA margin -220.43% van
- AML3D nak EBITDA margin -220.30% van
- Jayshree Chemicals nak EBITDA margin -219.42% van